Notably, CIMP-positive tumors have been observed to correlate with the presence of programmed cell death protein 1 (PD-1)-positive T cells in a subset of MSI-high cancers, enhancing the potential relevance of targeting CIMP-positive tumors in immunotherapeutic strategies [62]. This evidence concerns the gene PDCD1 and cancer.